Jubilant Life Sciences is currently trading at Rs. 179.35, up by 10.90 points or 6.47% from its previous closing of Rs. 168.45 on the BSE.
The scrip opened at Rs. 174.00 and has touched a high and low of Rs. 182.85 and Rs. 174.00 respectively. So far 1,50,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 219.25 on 18-Jun-2014 and a 52 week low of Rs. 116.10 on 17-Dec-2014.
Last one week high and low of the scrip stood at Rs. 182.85 and Rs. 166.00 respectively. The current market cap of the company is Rs. 2,854.00 crore.
The promoters holding in the company stood at 54.02% while Institutions and Non-Institutions held 22.47% and 23.50% respectively.
Jubilant Life Sciences, one of the leading players in nutrition market and the largest manufacturer of vitamin B3 (Niacin & Niacinamide) in the world, has increased the prices of Niacinamide by 10% with immediate effect, for non-contract customers and whenever existing contracts permit. Niacin & Niacinamide are forms of vitamin B3 and used in various pharmaceutical products.
Jubilant delivers unmatched advantages of consistent quality and availability of Vitamin B3 (Niacin & Niacinamide) to its customers globally. The company’s Nutritional Products business is backward integrated up to the initial raw material stage with global scale of operations.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in manufacture and supply of APIs, generics, specialty pharmaceuticals and life science ingredients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: